ValuEngine Lowers Horizon Pharma (HZNP) to Hold
ValuEngine downgraded shares of Horizon Pharma (NASDAQ:HZNP) from a buy rating to a hold rating in a report released on Tuesday morning.
Several other equities research analysts have also recently commented on HZNP. UBS Group set a $20.00 target price on Horizon Pharma and gave the stock a buy rating in a report on Thursday, November 30th. Cantor Fitzgerald set a $17.00 target price on Horizon Pharma and gave the stock a buy rating in a report on Friday, December 1st. BidaskClub raised Horizon Pharma from a hold rating to a buy rating in a report on Friday, December 22nd. Mizuho raised Horizon Pharma from a neutral rating to a buy rating and boosted their target price for the stock from $12.00 to $18.00 in a report on Friday, January 12th. Finally, Cowen reissued a buy rating and set a $24.00 target price on shares of Horizon Pharma in a report on Thursday, March 1st. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and ten have issued a buy rating to the company. Horizon Pharma currently has a consensus rating of Buy and an average target price of $18.64.
Horizon Pharma (HZNP) opened at $15.25 on Tuesday. Horizon Pharma has a 52-week low of $9.45 and a 52-week high of $16.02. The stock has a market capitalization of $2,560.00, a P/E ratio of -5.12, a PEG ratio of 0.67 and a beta of 1.34. The company has a current ratio of 1.63, a quick ratio of 1.54 and a debt-to-equity ratio of 1.91.
Several hedge funds and other institutional investors have recently bought and sold shares of the business. William Blair Investment Management LLC increased its holdings in shares of Horizon Pharma by 12.2% in the fourth quarter. William Blair Investment Management LLC now owns 8,826,079 shares of the biopharmaceutical company’s stock valued at $128,861,000 after buying an additional 958,414 shares in the last quarter. Sterling Capital Management LLC bought a new position in shares of Horizon Pharma in the fourth quarter valued at $1,340,000. Segall Bryant & Hamill LLC increased its holdings in shares of Horizon Pharma by 12.6% in the fourth quarter. Segall Bryant & Hamill LLC now owns 725,002 shares of the biopharmaceutical company’s stock valued at $10,585,000 after buying an additional 81,074 shares in the last quarter. Redmile Group LLC bought a new position in shares of Horizon Pharma in the fourth quarter valued at $292,000. Finally, Cowen Inc. bought a new position in shares of Horizon Pharma in the fourth quarter valued at $781,000. 86.77% of the stock is currently owned by institutional investors.
ILLEGAL ACTIVITY NOTICE: This story was published by Daily Political and is the sole property of of Daily Political. If you are reading this story on another site, it was copied illegally and reposted in violation of U.S. and international copyright law. The legal version of this story can be read at https://www.dailypolitical.com/2018/03/14/valuengine-lowers-horizon-pharma-hznp-to-hold-2.html.
About Horizon Pharma
Horizon Pharma Public Limited Company is a biopharmaceutical company. The Company is focused on identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs. As of December 31, 2016, the Company marketed 11 medicines through its orphan, rheumatology and primary care business units.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Horizon Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Pharma and related companies with MarketBeat.com's FREE daily email newsletter.